Gewinn- und Verlustrechnung von Medifast, Inc.

MED is reshaping its coach network around Executive Directors as productivity rises despite a sharp decline in active earning coaches.

MED's improving coach productivity and client retention point to stabilization, but a shrinking coach base remains a challenge.

Medifast's low valuation and improving coach productivity offer potential, but a shrinking coach base and weak growth keep the turnaround high risk.

Medifast stock gains 13.6% in a month as improving coach productivity and earnings expectations support momentum despite weaker revenue.

Medifast's Trilivy launch and cost cuts could support a Q4 profit turnaround, but shrinking revenue and its coach base keep risks high.

Medifast, Inc. has started to report stabilizing sales through improved coach productivity, shown again in the Q2 report. Stabilized sales provide a pathway to stabilize earnings. MED targets profitability by Q4 already, but the target has to be taken with caution. Due to MED's $15.2 in net cash per share, the stock seems attractive. I estimate 44% upside to $18.8 on the condition that earnings improve near breakeven.

MED tops Q2 earnings expectations despite lower sales, as rising coach productivity helps offset pressure from a shrinking coach network.

Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript

Medifast NYSE: MED reported second-quarter 2026 revenue of $76.4 million, down 27.6% from a year earlier, as its active earning coach base continued to decline amid the rapid adoption of GLP-1 medications across the traditional weight-loss category. The company posted a net loss of $3.1 million, or $0.28 per diluted share, compared with net income of $2.5 million, or $0.22 per share, in the prior-year quarter.

Medifast (MED) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to earnings of $0.04 per share a year ago.